Skip to search formSkip to main contentSkip to account menu

Enoxaparin

Known as: Enoxaparin [Chemical/Ingredient], Enoxaparine 
A low molecular weight, synthetic heparin. As an anticoagulant/antithrombotic agent, enoxaprin's mechanism of action is similar to that of heparin… 
National Institutes of Health

Related topics

Related topics

30 relations
0.4 ML Enoxaparin sodium 100 MG/ML Prefilled Syringe0.6 ML Enoxaparin sodium 100 MG/ML Prefilled Syringe [Lovenox]0.8 ML Enoxaparin sodium 100 MG/ML Prefilled Syringe [Lovenox]Angina, Unstable

Broader (2)

AnticoagulantsFibrinolytic Agents

Narrower (5)

ClexaneEMT-966Enoxaparin sodiumLovenox

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2007
Highly Cited
2007
Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY Trial.
Highly Cited
2007
Highly Cited
2007
Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY…
Highly Cited
2006
Highly Cited
2006
Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention.
BACKGROUND Despite its limitations, unfractionated heparin has been the standard anticoagulant used during percutaneous coronary… 
Highly Cited
2005
Highly Cited
2005
Enoxaparin Prevents Progression of Stages I and II Osteonecrosis of the Hip
In a prospective pilot study, we hypothesized that enoxaparin (60 mg/day for 12 weeks) would prevent progression of Stages I and… 
Highly Cited
2005
Highly Cited
2005
Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin.
Heparin-induced thrombocytopenia (HIT) is caused by platelet-activating IgG antibodies that recognize platelet factor 4 (PF4… 
Highly Cited
2004
Highly Cited
2004
Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial: study design and rationale.
Highly Cited
2001
Highly Cited
2001
Does the location of thrombosis determine the risk of disease recurrence in patients with proximal deep vein thrombosis?
Highly Cited
2000
Highly Cited
2000
The use of low molecular weight heparin in pediatric patients: a prospective cohort study.
Highly Cited
1999
Highly Cited
1999
Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis.
BACKGROUND Two phase III trials of enoxaparin for unstable angina/non-Q-wave myocardial infarction have shown it to be superior… 
Highly Cited
1996
Highly Cited
1996
Low-molecular-weight heparin in pediatric patients with thrombotic disease: a dose finding study.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)